DHPLC Determination of TPMT Polymorphisms.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00402090|
Recruitment Status : Unknown
Verified November 2006 by National Institute of Cancerología.
Recruitment status was: Recruiting
First Posted : November 22, 2006
Last Update Posted : November 22, 2006
|Condition or disease|
|Acute Lymphoblastic Leukemia|
Objectives: Determine by DHPLC analysis the frequency of TPMT polymorphisms in mestizos mexican population with acute lymphoblastic leukemia.
- To do a clinical correlation between the presence of polymorphism and thiopurine related- myelotoxicity.
- Inclusion criteria: Healthy volunteers or patients with acute lymphoblastic leukemia, age > 18 years, who attend to the National Institute of Cancerologia.
- Exclussion criteria: Patients with ALL, who are unable to have an adequate follow-up.
- Samples: Genomic DNA from peripheral blood leukocytes was isolated by standard methods. Known (wild-type and polymorphic) sequenced polymerase chain reaction (PCR) fragments of the TPMT gene were used as controls. TPMT gene fragments were amplified. PCR products were then analyzed by denaturating high performance liquid chromatography (DHPLC).
|Study Type :||Observational|
|Enrollment :||160 participants|
|Official Title:||Prevention of Thiopurines Related Toxicity Through the Determination by DHPLC TPMT Polymorphisms in Patients With ALL.|
|Study Start Date :||April 2005|
|Study Completion Date :||November 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00402090
|Contact: Myrna Candelaria, MD||(52)firstname.lastname@example.org|
|National Institute of Cancerologia||Recruiting|
|MExico city, DF, Mexico, 14080|
|Contact: Myrna Candelaria, MD (52)55-5628-04-79 email@example.com|
|Principal Investigator: Myrna Candelaria, MD|
|Principal Investigator:||Myrna Candelaria, MD||National Institute of Cancerologia|